Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma

NCT00631371 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00631371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00631371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
April 30, 2015
Enrollment
791 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma